Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
REGN sits 60% above its 52-week low of $476.487.
Summary
The U.S. FDA has granted accelerated approval for Regeneron's Otarmeni, the first gene therapy for severe-to-profound genetic hearing loss. This significant regulatory milestone adds a new, potentially high-value product to Regeneron's portfolio, targeting a specific rare condition. This approval follows a string of positive regulatory and partnership news for Regeneron in recent weeks. Separately, Regeneron announced an agreement with the U.S. government to lower prices on several current and future medicines and offer Praluent for free. While the gene therapy approval is a clear positive, the pricing agreement introduces a new, potentially impactful factor for future revenue and profitability, which could temper the overall market reaction. Traders will be watching for details on Otarmeni's market potential and the financial implications of the government pricing deal.
At the time of this announcement, REGN was trading at $763.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.